The analyst rating for PHARMARON is a Buy, primarily due to several positive catalysts. These include the upcoming announcement of the company's full-year results, which is expected to reflect accelerated order growth and lead to more optimistic guidance for the current year. Additionally, Citi views PHARMARON as a global leader in drug research and development, benefiting from the growth trend in China's Contract Research Organization (CRO) industry. The company's expansion into late-stage clinical development, commercial production, and the biopharmaceutical field further supports this positive outlook. The target price set by Citi is HKD45.
